MLLCF - Molecular Partners AG
| Previous Close | 6.59 |
| Open | 6.59 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 6.59 - 6.59 |
| 52 Week Range | 5.16 - 7.70 |
| Volume | |
| Avg. Volume | 101 |
| Market Cap | 237.615M |
| Beta (5Y Monthly) | 0.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.74 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireMolecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting
MP0317 demonstrates tumor-localized CD40 activation in tumor biopsies through target occupancy and immune cell activation MP0317 demonstrates a favorable safety profile across Q3W and Q1W regimens, including the highest dose tested, 10mg/kg (Q3W) Present data support planning of future combination studies with potential partners ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ:
- GlobeNewswire
Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 16, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that Patrick Amstuts, Chief Executive Officer, will participate in the 2023 RBC Capital Markets Global Healthcare Conference, in-person, May 16-17, 2023. Details: Fireside chat – Wednesday, May 17, 2023, at 2:05pm ET A copy of the prese
Simply Wall St.Getting In Cheap On Molecular Partners AG (VTX:MOLN) Is Unlikely
Molecular Partners AG's ( VTX:MOLN ) price-to-sales (or "P/S") ratio of 10.1x might make it look like a sell right now...
- GlobeNewswire
Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio Strategy
MP0533: Phase 1 trial of MP0533 for AML ongoing; initial recruitment is progressing well, and site expansion is ongoing; initial clinical results on track for Q4 2023 MP0317: Highest dose cohort (Q3W, 10mg/kg) now enrolling; clinical update at ASCO Radio DARPin Therapy (RDT): Presented preclinical data supporting the RDT platform at TAT 12 and AACR Outlook: Funded into 2026 with cash of CHF 232.4 million; total operating expenses of CHF 70 - 80 million expected for 2023 ZURICH-SCHLIEREN, Switzer
- Simply Wall St.
Investors in Molecular Partners (VTX:MOLN) have unfortunately lost 79% over the last five years
Some stocks are best avoided. It hits us in the gut when we see fellow investors suffer a loss. Spare a thought for...
- GlobeNewswire
Molecular Partners to Present Additional Preclinical Data Supporting the Company’s Radio DARPin Therapy Platform at AACR
Targeted radionuclide delivery platform strengthened by new safety and mechanistic dataData includes review of high tumor penetration potential of DARPins and reduced kidney accumulation via DARPin engineeringNew findings will be shared on April 18, 2023, at the American Association for Cancer Research Annual Meeting 2023 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developin
- GlobeNewswire
Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General Meeting
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 04, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the shareholders of the Company approved all motions proposed by the Board of Directors at the Annual General meeting by a wide majority. The Molecular Partners shareholders confirmed the approval of the annual review, the IFRS c
- GlobeNewswire
Molecular Partners Publishes Invitation to Annual General Meeting 2023
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today published the invitation to the Annual General Meeting 2023. The Annual General Meeting will be held on Tuesday, April 04, 2023, 14.00 CET (doors open at 13.30 CET), at startup space, Wiesenstrasse 10A, 8952 Schlieren, Switzerland. Invitation t
- Simply Wall St.
Molecular Partners Full Year 2022 Earnings: Beats Expectations
Molecular Partners ( VTX:MOLN ) Full Year 2022 Results Key Financial Results Revenue: CHF189.6m (up by CHF179.8m from...
- GlobeNewswire
Molecular Partners Reports Corporate Highlights From Q4 2022 and Key Financials for Full Year 2022
Research & Development Highlights: Initiated Phase 1 study of MP0533, a novel tri-specific T-cell engager for the treatment of acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS)Presented preclinical data supporting the unique design and mechanism of MP0533 at the 64th American Society of Hematology (ASH) Annual Meeting and ExpositionEstablished Radio DARPin Therapy (RDT) Platform, formally selecting tumor-associated protein Delta-like ligand 3 (DLL3) as a first targetPrese
- GlobeNewswire
Molecular Partners to Hold Conference Call to Discuss Fourth Quarter and Full Year 2022 Results and Present at the 43rd Annual Cowen Health Care Conference
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will issue a press release summarizing its highlights and financial results for the fourth quarter and full year of 2022, followed by an investor call the following day. Chief Executive Officer Patrick Amstutz will also deliver a company presentation
- GlobeNewswire
Molecular Partners Presents New Preclinical Data Supporting Its Radio DARPin Therapy Platform
Proprietary Radio DARPin Therapy Platform designed to deliver high amount of radioactivity to the tumor while maintaining low accumulation in other tissues Data reveal engineering approach to significantly reduce kidney accumulation of DARPin-based radiotherapeutic candidates to potentially expand therapeutic window of the class Several in-house and Novartis-partnered DARPin-based radiotherapeutic programs in indications with high unmet medical need currently underway Data to be presented at the
- GlobeNewswire
Molecular Partners to Present at SVB Leerink Global Healthcare Conference
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in the SVB Leerink Global Healthcare conference (Virtual). Conference Presentation Details: SVB Leerink Global Healthcare Conference Wednesday, February 15, 202
- GlobeNewswire
Molecular Partners Initiates Clinical Study of Trispecific Candidate MP0533 for the Treatment of Acute Myeloid Leukemia
Unique avidity driven mechanism engages CD3 on T cells when binding either two or three tumor-associated antigens to enhance selectivity for AML cellsPreclinical data demonstrated that MP0533 can selectively target and kill both leukemic blast cells and stem cells, while sparing healthy cells ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 16, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built p
- Simply Wall St.
Hedge funds own 28% of Molecular Partners AG (VTX:MOLN) shares but individual investors control 41% of the company
A look at the shareholders of Molecular Partners AG ( VTX:MOLN ) can tell us which group is most powerful. With 41...
- GlobeNewswire
Molecular Partners Provides Updates at 41st Annual JPM Healthcare Conference
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 08, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR : Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced several developments in its infectious disease and oncology portfolios. These include: DARPin Radioligand Therapy platform progressing well. Disclosure of the tumor-associated protein Delta-
- GlobeNewswire
Molecular Partners to Present at 41st Annual JP Morgan Healthcare Conference and Swiss Investor Conferences
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in the 41st annual JP Morgan Healthcare Conference in San Francisco, CA. In addition, members of Molecular Partners management will participate in several upcom
- GlobeNewswire
Molecular Partners Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML
New data indicates potential to expand the therapeutic window and improve safety compared to existing T-cell engagersTri-specific T-cell engager resulted in AML cell-specific cytotoxicity with minimal off-tumor toxicityPhase I clinical trial evaluating safety and dose of MP0533 in patients with Relapsed/Refractory AML and high-risk MDS to start imminently ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinica
- Simply Wall St.
Molecular Partners AG's (VTX:MOLN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Molecular Partners (VTX:MOLN) has had a great run on the share market with its stock up by a significant 20% over the...
- GlobeNewswire
Molecular Partners Presents Positive Interim Safety and Mechanistic Data From Ongoing Phase 1 Trial of MP0317 for Treatment of Solid Tumors
First clinical observation of tumor localized CD40 activation provided by MP0317No systemic or dose-limiting toxicities observed, a key parameter for CD40 agentsDose escalation remains ongoing with study recruitment anticipated to complete in 1H 2023 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR : Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built
- Simply Wall St.
Investors in Molecular Partners (VTX:MOLN) have unfortunately lost 77% over the last five years
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut...
- GlobeNewswire
Molecular Partners Announces Acceptance of Oral Presentation at the Annual American Society of Hematology Meeting
- Company will also host a reception with Key Opinion Leaders in New Orleans -ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced the acceptance of an upcoming presentation at the American Society of Hematology (ASH) Annual Meeting, held in New Orleans, LA from December 9-13, 2022. The
- GlobeNewswire
Molecular Partners Announces Upcoming Participation in Investor and Scientific Conferences
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the team will present at several upcoming investor and scientific conferences. Initial data from the company’s ongoing Phase 1 Trial of MP0317 for the treatment of solid tumors will be presented as a poster at the 2022 Society for
- GlobeNewswire
Interim Management Statement Q3 2022: Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated by Year-End
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its interim management statement for the quarter ending September 30, 2022. “We have made notable progress this quarter across our oncology programs including MP0317, MP0533, as well as our D
- GlobeNewswire
Molecular Partners Announces Planned Departure of Chief Financial Officer
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Financial Officer, Andreas Emmenegger, will depart the company at the end of 2022 to pursue a new position in another company. Molecular Partners is beginning the process of id